METTL3 and glioblastoma: METTL3 KD reduced total m6A modification (Figure S3B) and restored the sensitivity of TMZ‐resistant GBM cells to TMZ treatment (Figures 3A and S3C), while ectopic expression of METTL3 (Figure S3D) enhanced resistance to TMZ (Figure S3E).